#1
#1 out of 1
business1d ago
Cellectis (NASDAQ:CLLS) Stock Price Crosses Below 200 Day Moving Average - Time to Sell?
- Cellectis stock fell below its 200-day moving average, trading as low as $3.73 while the MA stood at $4.02.
- Analysts show mixed sentiment with a Moderate Buy consensus and an average target of $6.75.
- Q1 results showed a negative EPS miss but revenue beat expectations.
- Market cap sits around $374 million amid profitability challenges.
- Weiss Ratings maintains a sell rating despite other mixed analyst views.
- Institutional investors have increased exposure, signaling ongoing interest.
- Cellectis specializes in gene-edited cell therapies for oncology with CAR-T candidates.
- Marketbeat frames the alert as fast, unbiased coverage of the stock.
- Analysts provided price targets and ratings across multiple firms.
- Cellectis' quarter showed revenue beat expectations despite a negative EPS.
- MarketBeat summarizes stocks to own in May, referencing Cellectis alongside others.
Vote 0